Cullinan Oncology
CGEM
103 hedge funds and large institutions have $330M invested in Cullinan Oncology in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 11 closing their positions.
93% more call options, than puts
Call options by funds: $29K | Put options by funds: $15K
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
6% more funds holding
Funds holding: 97 → 103 (+6)
0.33% less ownership
Funds ownership: 82.37% → 82.04% (-0.33%)
9% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 34
17% less capital invested
Capital invested by funds: $396M → $330M (-$66.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.17M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.1M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.52M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$827K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$625K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$47.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.69M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.41M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.84M |
| 5 |
BlackRock
New York
|
-$2.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
101
Woodline Partners
San Francisco,
California
| – | -$2.07M | -195,839 | Closed |
|
102
Norges Bank
Oslo,
Norway
| – | -$1.08M | -101,900 | Closed |
|
|
HS
103
HighVista Strategies
Boston,
Massachusetts
| – | -$843K | -79,918 | Closed |
|
104
Victory Capital Management
San Antonio,
Texas
| – | -$443K | -41,980 | Closed |
|
105
Acadian Asset Management
Boston,
Massachusetts
| – | -$178K | -16,927 | Closed |
|
106
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$153K | -13,891 | -100% |
|
|
FRM
107
Fox Run Management
Greenwich,
Connecticut
| – | -$110K | -10,412 | Closed |
|
|
TI
108
Trexquant Investment
Stamford,
Connecticut
| – | -$108K | -10,249 | Closed |
|
109
Invesco
Atlanta,
Georgia
| – | -$106K | -10,057 | Closed |
|
|
ACM
110
Aquatic Capital Management
Chicago,
Illinois
| – | -$75K | -7,200 | Closed |
|
|
QCG
111
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$6.66K | -631 | Closed |
|
|
QT
112
Quantbot Technologies
New York
| – | -$4.22K | -400 | Closed |
|
CGEM Hedge Fund Activity: Q1 2023 in Review
103 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2023, worth a combined $330M — down 17% from $396M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CGEM positions and 11 closed out — a net gain of 6 holders — while 31 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.17M. The largest seller was BVF Inc, cutting an estimated $47.5M.
- 103 institutional investors held Cullinan Oncology (CGEM) as of Q1 2023, up from 97 in Q4 2022.
- Funds reported $330M of Cullinan Oncology stock for Q1 2023, down 17% quarter-over-quarter.
- 17 funds opened new Cullinan Oncology positions in Q1 2023 and 11 closed out, a net change of +6 holders.
- The largest Cullinan Oncology buyer in Q1 2023 was Citadel Advisors, an estimated $4.17M added.
- The largest Cullinan Oncology seller in Q1 2023 was BVF Inc, an estimated $47.5M sold.
Based on aggregated 13F filings for Q1 2023.